Immuron Announces Strategic Investment In UK-Based Gut Health Company
Summary
None Potential adjustment to share percentage for Immuron dependent on Aterias performance during its CY2023. None Ateria Health Ltd is a U.K.-based health and wellness company that has developed a novel irritable bowel syndrome (IBS) treatment product with distribution capability in the U.K. and Australian markets with research interests in Australia. It is derived from barley and comprises a mixture of natural plant-derived enzymes involved in breaking down and metabolizing foods. Ateria has launched its first brand JUVIA, targeting IBS in Q3 CY22 in the U.K. None The strategic investment advances Immurons objective to enter the broader IBS market and strengthen the distribution of Immurons Travelan products through B2C online platforms and pharmacy and retail channels in target markets. None Price Action: IMRN shares are down 1% at $1.98 on the last check Thursday.See more from Benzinga None At Higher Doses, Otonomys OTO-413 Shows No Clinical Benefit In Hearing Loss None Trump Has 21 Days To Declare Which Mar-a-Lago Documents He Wants To Keep Off-Limits In Criminal ProbeDont miss real-time alerts on your stocks - join Benzinga Pro for free!